Thrombosis and Systemic Lupus Erythematosus: The Hopkins Lupus Cohort Perspective
Abstract
Vascular damage in systemic lupus erythematosus (SLE) occurs through vasculitis, premature atherosclerosis, and hypercoagulability (predominantly due to the antiphospholipid antibody syndrome). In the Hopkins Lupus Cohort, a prospective cohort study, the incidence of thrombosis is 2 per 100 person-years of follow-up. Markers of immune-complex mediated injury (high anti-dsDNA and low C3), atherosclerosis (hypertension, hyperlipidemia, homocysteine) and antiphospholipid antibodies (lupus anticoagulant or anticardiolipin) are independent predictors of thrombosis. Hydroxychloroquine use is protective against future thrombosis.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Prior retrospective and prospective studies have shown that hydroxychloroquine lowers the risk of arterial and venous thrombosis in systemic lupus erythematosus.
“Multiple retrospective and a few prospective studies (3–13) have found that hydroxychloroquine (HCQ) reduces the risk of arterial and venous thrombosis.”
From Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus (2021) · cites this paper as [12]
The citation lists haven’t been fetched yet
References 13 · Cited by 176
Research works printed but not linked: 4
- Petri M, 1996, Plasma homocysteine is a risk factor for stroke in patients with systemic lupus erythematosus
- McNeil HP, 1991, Immunology and clinical importance of antiphospholipid antibodies. Adv. Immunol., 49, 193
- Petri M, 1995, Arthritis Rheum., 38
- Petri M, 1996, Am. J. Med.
- Authors
- Petri, M.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Petri, M.
- ORCID
- Petri, M.
- Venue
- Scandinavian Journal of Rheumatology
- Publisher
- Informa UK Limited
- Published
- 1996-01
- Volume
- 25
- Issue
- 4
- Pages
- 191-193
- ISSN
- 0300-9742 (ISSN-L)
- 1502-7732
- OpenAlex
- W1989924681
- Semantic Scholar
- 4da670090a512eed265902180d038e523c169c42
- Cited by
- 176
- References
- 13
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 3 · 2022: 4 · 2021: 6 · 2020: 9 · 2018: 5 · 2017: 2 · 2016: 6 · 2015: 3 · 2014: 9 · 2013: 9 · 2012: 4
- FWCI
- 1.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Scandinavian Journal of Rheumatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Vasculitis and related conditions
- Keywords
- systemic lupus erythematosus, thrombosis, antiphospholipid antibodies, antiphospholipid syndrome, lupus anticoagulant, anticardiolipin antibodies, atherosclerosis, hypercoagulability, vasculitis, anti-dsDNA antibodies, complement C3, hydroxychloroquine, thrombosis risk factors
- MeSH terms
- Humans, Lupus Erythematosus, Systemic, Risk Factors, Thrombosis, Cohort Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
